- Home
- KIM vs RVMD Comparison
KIM vs RVMD Comparison
Compare KIM & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$20.59
HOLD
Current Price
$97.52
Company Overview
Basic Information| Metric | KIM | RVMD |
|---|---|---|
| Founded | 1958 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 15.2B |
| IPO Year | 1991 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KIM | RVMD |
|---|---|---|
| Price | $20.59 | $97.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 17 |
| Target Price | $24.17 | ★ $77.47 |
| AVG Volume (30 Days) | ★ 4.5M | 2.9M |
| Earning Date | 02-12-2026 | 02-25-2026 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | ★ 57.13 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,123,057,000.00 | N/A |
| Revenue This Year | $5.60 | N/A |
| Revenue Next Year | $3.39 | $714.50 |
| P/E Ratio | $24.42 | ★ N/A |
| Revenue Growth | ★ 8.14 | N/A |
| 52 Week Low | $17.93 | $29.17 |
| 52 Week High | $23.65 | $105.00 |
Technical Indicators
Market Signals| Indicator | KIM | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 56.08 | 88.59 |
| Support Level | $19.97 | $76.28 |
| Resistance Level | $20.46 | $80.48 |
| Average True Range (ATR) | 0.28 | 4.87 |
| MACD | 0.05 | 2.13 |
| Stochastic Oscillator | 84.38 | 91.55 |
Price Performance
Historical Comparison KIM
RVMD
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.